Paul
03-29-2004, 07:02 AM
AVANIR Pharmaceuticals (AMEX:AVN) presented preclinical data on its experimental compound AVP-893 and four related analogs at the 2004 Annual Meeting of the American Association for Cancer Research (AACR) in Orlando Florida. In vitro these compounds possess potent anti-proliferative activity and are most potent against melanoma leukemia breast prostate kidney and central nervous system tumor types.
AVANIR's anti-cancer compounds are active alone or in combination with established chemotherapy in several in vivo tumor models. The compounds have been tested in combination models with doxorubicin cisplatin or paclitaxel and have shown substantial activity over that observed with either agent alone. Preclinical tests also show that the compounds are active following daily intraperitoneal and intravenous injections. Three of the compounds demonstrate activity following daily oral dosing. In all of these studies AVP-893 and other compounds of this series show a favorable toxicity profile even when dosed daily for up to three months.
Early compound screening by the National Cancer Institute (NCI) suggested that AVP-893 represents a new class of anti-cancer drugs. Data presented at the 2004 AACR meeting suggests that the mechanism by which these compounds act is also novel and not duplicated among anti-cancer drugs that are currently marketed or those known to be in development for cancer or other indications.
The abstract accepted for presentation at the 95th Anniversary AACR meeting will be published in the journal Cancer Research.
AVANIR's anti-cancer compounds are active alone or in combination with established chemotherapy in several in vivo tumor models. The compounds have been tested in combination models with doxorubicin cisplatin or paclitaxel and have shown substantial activity over that observed with either agent alone. Preclinical tests also show that the compounds are active following daily intraperitoneal and intravenous injections. Three of the compounds demonstrate activity following daily oral dosing. In all of these studies AVP-893 and other compounds of this series show a favorable toxicity profile even when dosed daily for up to three months.
Early compound screening by the National Cancer Institute (NCI) suggested that AVP-893 represents a new class of anti-cancer drugs. Data presented at the 2004 AACR meeting suggests that the mechanism by which these compounds act is also novel and not duplicated among anti-cancer drugs that are currently marketed or those known to be in development for cancer or other indications.
The abstract accepted for presentation at the 95th Anniversary AACR meeting will be published in the journal Cancer Research.